Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers

Pharmacology and Therapeutics

Volumn 125, Issue 3, 2010, Pages 464-475

  Dörner, Thomas ^a   Kinnman, Nils ^b   Tak, Paul P ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MERCK SERONO S A   (Switzerland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

B cell targeting drugs; Biomarker; Mechanism of action; Rheumatoid arthritis; Sj gren's syndrome; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; BIOLOGICAL MARKER; BLINATUMOMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; FC RECEPTOR; IMMUNOGLOBULIN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VELTUZUMAB;

B LYMPHOCYTE; CELL SELECTION; CLINICAL TRIAL; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; HUMAN; INFLAMMATION; LEUKEMIA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOMARKERS, PHARMACOLOGICAL; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL;

EID: 76849086881     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.01.001     Document Type: Review

References (148)

1. Abrahams V.M., Cambridge G., Lydyard P.M., and Edwards J.C. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 43 (2000) 608-616
2. Ahuja A., Anderson S.M., Khalil A., and Shlomchik M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 105 (2008) 4802-4807
3. Alexander T., Thiel A., Rosen O., Massenkeil G., Sattler A., Kohler S., et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113 (2009) 214-223
4. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
5. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590
6. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 (2008) 974-977
7. Becker-Merok A., Nikolaisen C., and Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15 (2006) 570-576
8. Benson M.J., Dillon S.R., Castigli E., Geha R.S., Xu S., Lam K.P., et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180 (2008) 3655-3659
9. Buch M.H., Boyle D.L., Rosengren S., Saleem B., Reece R.J., Rhodes L.A., et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 68 (2009) 1220-1227
10. Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48 (2003) 2146-2154
11. Cambridge G., Stohl W., Leandro M.J., Migone T.S., Hilbert D.M., and Edwards J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54 (2006) 723-732
12. Cambridge G., Isenberg D.A., Edwards J.C., Leandro M.J., Migone T.S., Teodorescu M., et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67 (2008) 1011-1016
13. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 (2009) 4834-4840
14. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., and Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189 (1999) 1639-1648
15. Cheema G.S., Roschke V., Hilbert D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 (2001) 1313-1319
16. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
17. Clavel C., Nogueira L., Laurent L., Iobagiu C., Vincent C., Sebbag M., et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 58 (2008) 678-688
18. Cohen S.B. Updates from B cell trials: efficacy. J Rheumatol Suppl 77 (2006) 12-17
19. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
20. Collins C.E., Gavin A.L., Migone T.S., Hilbert D.M., Nemazee D., and Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 8 (2006) R6
21. Cragg M.S., and Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004) 2738-2743
22. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56 (2007) 4142-4150
23. d'Argouges S., Wissing S., Brandl C., Prang N., Lutterbuese R., Kozhich A., et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 33 (2009) 465-473
24. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67 (2008) 1541-1544
25. Dass S., Rawstron A.C., Vital E.M., Henshaw K., McGonagle D., and Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58 (2008) 2993-2999
26. De Vita S., and Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 5 (2006) 443-448
27. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46 (2002) 2029-2033
28. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57 (2007) 310-317
29. DiLillo D.J., Hamaguchi Y., Ueda Y., Yang K., Uchida J., Haas K.M., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180 (2008) 361-371
30. Dillon S., Harder B., Lewis K., Moore M., Liu H., Bukowski T., et al. BLyS/APRIL heterotrimers activate human B cells, are neutralised by atacicept, and are elevated in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Ann Rheum Dis 68 Suppl. 3 (2009) 368
31. Dorken B., Moldenhauer G., Pezzutto A., Schwartz R., Feller A., Kiesel S., et al. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136 (1986) 4470-4479
32. Dörner T., and Burmester G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 15 (2003) 246-252
33. Dörner T., and Burmester G.R. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 20 (2008) 263-268
34. Dörner T., and Goldenberg D.M. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag 3 (2007) 953-959
35. Dörner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R74
36. Edwards J.C., Cambridge G., and Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology 97 (1999) 188-196
37. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
38. Edwards J.C., Leandro M.J., and Cambridge G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 8 (2005) 175-192
39. Edwards J.C., Cambridge G., and Leandro M.J. Repeated B-cell depletion in clinical practice. Rheumatology (Oxford) 46 (2007) 1509
40. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
41. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008) 1516-1523
42. Feuchtenberger M., Muller S., Roll P., Waschbisch A., Schafer A., Kneitz C., et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J 2 (2008) 81-88
43. Finckh A., Ciurea A., Brulhart L., Moller B., Walker U.A., Courvoisier D., et al. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?. Ann Rheum Dis 69 (2010) 387-393
44. Food and Drug Administration. FDA Public Health Advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment (2006). http://www.fda.gov/cder/drug/ http://www.fda.gov/cder/drug/
45. Furie R., Stohl W., Ginzler E.M., Becker M., Mishra N., Chatham W.W., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10 (2008) R109
46. Genentech press release. Phase III study of Rituxan in lupus nephritis did not meet primary endpoint (2009). http://www.gene.com/gene/news/press-releases/displaydo?method= detail&id= 11947&categoryid=4 http://www.gene.com/gene/news/press-releases/displaydo?method= detail&id=11947&categoryid=4
47. Genovese M.C., Kaine J.L., Lowenstein M.B., Giudice J.D., Baldassare A., Schechtman J., et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58 (2008) 2652-2661
48. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008) 2968-2980
49. Gerlag D.M., and Tak P.P. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol 22 (2008) 311-323
50. Gerlag D.M., Haringman J.J., Smeets T.J., Zwinderman A.H., Kraan M.C., Laud P.J., et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 50 (2004) 3783-3791
51. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109 (2002) 59-68
52. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
53. Hansen A., Lipsky P.E., and Dorner T. B cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 9 (2007) 218
54. Hiepe F., and Radbruch A. B cells in autoimmunity: more than antibodies?. Blood 106 (2005) 2227
55. Horton H.M., Bernett M.J., Pong E., Peipp M., Karki S., Chu S.Y., et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68 (2008) 8049-8057
56. Hoyer B.F., Manz R.A., Radbruch A., and Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050 (2005) 124-133
57. Ingold K., Zumsteg A., Tardivel A., Huard B., Steiner Q.G., Cachero T.G., et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201 (2005) 1375-1383
58. Jacobi A.M., and Diamond B. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 202 (2005) 341-344
59. Jacobi A.M., Goldenberg D.M., Hiepe F., Radbruch A., Burmester G.R., and Dorner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 67 (2008) 450-457
60. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 69 (2010) 88-96
61. Kavanaugh A., Rosengren S., Lee S.J., Hammaker D., Firestein G.S., Kalunian K., et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 67 (2008) 402-408
62. Kawasaki A., Tsuchiya N., Fukazawa T., Hashimoto H., and Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 3 (2002) 424-429
63. Kawasaki A., Tsuchiya N., Ohashi J., Murakami Y., Fukazawa T., Kusaoi M., et al. Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese. Rheumatology (Oxford) 46 (2007) 776-782
64. Keystone E., Wherry J., and Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 24 (1998) 629-639
65. Kim H.J., Krenn V., Steinhauser G., and Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 162 (1999) 3053-3062
66. Koyama T., Tsukamoto H., Miyagi Y., Himeji D., Otsuka J., Miyagawa H., et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 64 (2005) 1065-1067
67. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44 (2005) 1542-1545
68. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 613-620
69. Leandro M.J., Cooper N., Cambridge G., Ehrenstein M.R., and Edwards J.C. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 46 (2007) 29-36
70. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., and Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35 (2008) 826-833
71. Linnik M.D., Hu J.Z., Heilbrunn K.R., Strand V., Hurley F.L., and Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 52 (2005) 1129-1137
72. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2 (2001) 764-766
73. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
74. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61 (2009) 482-487
75. Mackay F., Groom J.R., and Tangye S.G. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 19 (2007) 406-413
76. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
77. McKay J., Chwalinska-Sadowska H., Boling E., Valente R., Limanni A., Racewicz A., et al. Belimumab (BmAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population. Arthritis Rheum 52 Suppl. 9 (2005) S710-S711
78. Meijer J.M., Pijpe J., Vissink A., Kallenberg C.G., and Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 68 (2009) 284-285
79. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. ACR/ARHP Annual Scientific Meeting, San Francisco, CA, USA (2008, October 24-29) Abstract L12
80. Mitchison N.A., and Wedderburn L.R. B cells in autoimmunity. Proc Natl Acad Sci U S A 97 (2000) 8750-8751
81. Moller B., Aeberli D., Eggli S., Fuhrer M., Vajtai I., Vogelin E., et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 11 (2009) R62
82. Molloy E.S., and Calabrese L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 8 (2008) 144-146
83. Morel J., Roubille C., Planelles L., Rocha C., Fernandez L., Lukas C., et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 68 (2009) 997-1002
84. Moser K., Muehlinghaus G., Manz R., Mei H., Voigt C., Yoshida T., et al. Long-lived plasma cells in immunity and immunopathology. Immunol Lett 103 (2006) 83-85
85. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167 (1988) 332-344
86. Navarra S., Guzman R., Gallacher A., Levy R.A., Li E.K., Jimenez R., et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. American College of Rheumatology Annual Scientific Meeting Philadelphia, United States (2009) October 16-21. LBA1
87. Nestorov I., Munafo A., Papasouliotis O., and Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 48 (2008) 406-417
88. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., and Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66 (2007) 1259-1262
89. Nicholas M.W., Dooley M.A., Hogan S.L., Anolik J., Looney J., Sanz I., et al. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol 126 (2008) 189-201
90. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (2007) 1162-1167
91. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19 (2009) 12-19
92. Odendahl M., Jacobi A., Hansen A., Feist E., Hiepe F., Burmester G.R., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165 (2000) 5970-5979
93. Ohata J., Zvaifler N.J., Nishio M., Boyle D.L., Kalled S.L., Carson D.A., et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 174 (2005) 864-870
94. Pena-Rossi C., Nasonov E., Stanislav M., Yakusevich V., Ershova O., Lomareva N., et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18 (2009) 547-555
95. Pepper R., Griffith M., Kirwan C., Levy J., Taube D., Pusey C., et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24 (2009) 3717-3723
96. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
97. Popa C., Leandro M.J., Cambridge G., and Edwards J.C. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46 (2007) 626-630
98. Press O.W., Appelbaum F., Ledbetter J.A., Martin P.J., Zarling J., Kidd P., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69 (1987) 584-591
99. Reininger L., Winkler T.H., Kalberer C.P., Jourdan M., Melchers F., and Rolink A.G. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB × NZW) F1 mice. J Exp Med 184 (1996) 853-861
100. Reis E.A., Athanazio D.A., Lima I., Silva O.e., Andrade J.C., Jesus R.N., et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 29 (2009) 469-475
101. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther 10 (2008) 294-309
102. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54 (2006) 2377-2386
103. Roll P., Dorner T., and Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58 (2008) 1566-1575
104. Roschke V., Sosnovtseva S., Ward C.D., Hong J.S., Smith R., Albert V., et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169 (2002) 4314-4321
105. Rosengren S., Wei N., Kalunian K.C., Zvaifler N.J., Kavanaugh A., and Boyle D.L. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 10 (2008) R105
106. Sato S., Ono N., Steeber D.A., Pisetsky D.S., and Tedder T.F. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 157 (1996) 4371-4378
107. Sato T., Ishikawa S., Akadegawa K., Ito T., Yurino H., Kitabatake M., et al. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur J Immunol 34 (2004) 3346-3358
108. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66 (2007) 351-357
109. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115 (2005) 3083-3092
110. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
111. Sfikakis P.P., Karali V., Lilakos K., Georgiou G., and Panayiotidis P. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion. Clin Immunol 132 (2009) 19-31
112. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54 (2006) 2970-2982
113. Stashenko P., Nadler L.M., Hardy R., and Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 125 (1980) 1678-1685
114. Stashenko P., Nadler L.M., Hardy R., and Schlossman S.F. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A 78 (1981) 3848-3852
115. Steinfeld S.D., Tant L., Burmester G.R., Teoh N.K., Wegener W.A., Goldenberg D.M., et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8 (2006) R129
116. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48 (2003) 3475-3486
117. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Roschke V., et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 63 (2004) 1096-1103
118. Sutter J.A., Kwan-Morley J., Dunham J., Du Y.Z., Kamoun M., Albert D., et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 126 (2008) 282-290
119. Tahir H., Rohrer J., Bhatia A., Wegener W.A., and Isenberg D.A. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 44 (2005) 561-562
120. Tak P.P., Cohen S., Emery P., Saadeh C.K., De Vita S., Donohue J.P., et al. Baseline autoantibody status (RF, anti-CCP) and clinical response following the first treatment course with rituximab. Arthritis Rheum 54 (2006) S368
121. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58 (2008) 61-72
122. Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., and Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167 (2001) 4710-4718
123. Tamimoto Y., Horiuchi T., Tsukamoto H., Otsuka J., Mitoma H., Kimoto Y., et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 47 (2008) 821-827
124. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43 (2000) 38-47
125. Tedder T.F., Poe J.C., and Haas K.M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88 (2005) 1-50
126. Teng Y.K., Levarht E.W., Hashemi M., Bajema I.M., Toes R.E., Huizinga T.W., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56 (2007) 3909-3918
127. Teng Y.K., Engels M.C., and van Laar J.M. CD22 is not expressed merely on B cells: comment on the article by Vos et al. Arthritis Rheum 58 (2008) 911-912
128. Teng Y.K., Levarht E.W., Toes R.E., Huizinga T.W., and van Laar J.M. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 68 (2009) 1011-1016
129. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293 (2001) 2108-2111
130. Thurlings R.M., Vos K., Gerlag D.M., and Tak P.P. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 58 (2008) 3657-3664
131. Thurlings R.M., Vos K., Wijbrandts C.A., van Schaardenburg D., Gerlag D.M., and Tak P.P. CD22 is not expressed merely on B cells: comment on the article by Vos et al; Author reply. Arthritis Rheum 58 (2008) 912
132. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., and Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67 (2008) 917-925
133. Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44 (2005) 176-182
134. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66 (2007) 470-475
135. Toubi E., Kessel A., Slobodin G., Boulman N., Pavlotzky E., Zisman D., et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 818-820
136. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008) 244-279
137. Valleala H., Korpela M., Mottonen T., Hienonen-Kempas T., Kauppi M., Hannonen P., et al. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol 38 (2009) 323-327
138. van Zeben D., Hazes J.M., Zwinderman A.H., Cats A., van der Voort E.A., and Breedveld F.C. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 51 (1992) 1029-1035
139. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., Portales-Perez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8 (2006) R83
140. Vos K., Thurlings R.M., Wijbrandts C.A., van S.D., Gerlag D.M., and Tak P.P. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56 (2007) 772-778
141. Wallace D.J., Lisse J., Stohl W., McKay J., Boling E., Merrill J.T., et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 54 Suppl. 9 (2006) S790
142. Walsh C.A., Fearon U., FitzGerald O., Veale D.J., and Bresnihan B. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin Exp Rheumatol 26 (2008) 656-658
143. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
144. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
145. Wijbrandts C.A., Vergunst C.E., Haringman J.J., Gerlag D.M., Smeets T.J., and Tak P.P. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 56 (2007) 3869-3871
146. Youinou P., Devauchelle V., Hutin P., Le B.R., Saraux A., and Pers J.O. A conspicuous role for B cells in Sjogren's syndrome. Clin Rev Allergy Immunol 32 (2007) 231-237
147. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201 (2005) 703-711
148. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166 (2001) 6-10